Cognition In Older Breast Cancer Survivors: Treatment Exposure, APOE, & Smoking
老年乳腺癌幸存者的认知:治疗暴露、APOE、
基本信息
- 批准号:8909079
- 负责人:
- 金额:$ 69.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-25 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdjuvant ChemotherapyAdultAffectAftercareAgeAgingAging-Related ProcessAnimalsApolipoproteinsAttentionBenefits and RisksBrainBreast Cancer TreatmentBreast Cancer survivorCancer ControlCancer PatientCancer SurvivorCognitionCognitiveCognitive agingComorbidityDataDevelopmentDiagnosisEducationElderlyEnrollmentExposure toFamilyFoundationsFrightGeneticGenetic PolymorphismGeriatricsGoalsGrowthHealthHealth StatusHealthcare SystemsImageImpaired cognitionIndividualInterventionKnowledgeLifeLife StyleLong-Term SurvivorsLongitudinal StudiesMalignant NeoplasmsMeasuresMedicalMinorModelingMorbidity - disease rateNeuropsychological TestsNeuropsychologyNicotinic ReceptorsPatientsPatternPerformancePersonal SatisfactionPhasePopulationPrevalence StudyQuality of lifeRaceResearch DesignRiskSamplingSmokerSmokingSmoking HistoryStructureSurvivorsTechniquesTherapeuticTimeTreatment Factoraging populationcancer therapychemotherapycognitive capacitycognitive changecognitive functioncognitive performancecognitive reservecohortfrailtyhigh riskhormone therapyhuman old age (65+)innovationlifestyle factorslongitudinal designmalignant breast neoplasmmortalitynon-smokernormal agingolder patientolder womenoncologypreventprospective
项目摘要
DESCRIPTION (provided by applicant): Cognitive decline is one of the most feared consequences of aging among older adults and even minor changes in cognitive function can seriously impact function, ability to live independently, and quality of life. The trajectory of cognitive change with normal aging is influenced by factors including genetics, cognitive reserve, lifestyle, frailty, and comorbid medical conditions. Although there are compelling data suggesting a relationship between cancer, cancer therapy, and cognitive impairment the vast majority of these studies have focused on younger patients (<65 years old) and few studies have focused on 5+ year survivors. However, the majority of cancer survivors are older adults. Furthermore, those who were treated at an older age may be more vulnerable to cognitive decline because factors that influence normal cognitive aging may interact with cancer treatments to increase vulnerability. The objective of this application is to unite the fields of geriatrics, neuropsychology, oncology, and genetics to study the prevalence and trajectory of cognitive impairment in a cohort of older, long-term (5-15 years) survivors of breast cancer and matched healthy controls. Using a prospective, longitudinal study design, we will pursue the following specific aims while controlling for comorbidity and frailty: Aim 1: Examine the association of APOE status, smoking history, and therapeutic exposures on the cognitive performance among older breast cancer survivors compared to controls (age-, race- and education-matched) Aim 2: Utilize Growth Mixture Modeling techniques to determine trajectories of longitudinal change in cognitive function among older breast cancer survivors and controls (age-, race- and education-matched): Aim 3: Explore associations among cognitive reserve, APOE, smoking history and therapeutic exposures on cognitive functioning at study entry and the pattern of longitudinal change. This study is significant because it will fill a major gap in knowledge regarding the factors that increase risk for cognitive decline in older breast cancer survivors. These data are critical in order to weigh the risks and benefits of cancer treatment in the growing aging population. This study is innovative because it will examine the interactions of therapeutic exposures, genetic polymorphisms, and smoking history in predicting differences in cognitive performance between breast cancer survivors and controls controlling for burden of comorbidity and frailty. Furthermore, the longitudinal design will inform whether the trajectory of
cognitive change for cancer survivors parallels healthy controls (phase shift hypothesis) or demonstrates a steeper slope (accelerated aging hypothesis). These data will serve as a foundation to identify older breast cancer survivors at risk for cognitive impairment and guide the
development of rationale interventions to decrease this risk, with the ultimate goal of preserving the cognitive function and well-being of older survivors of cancer.
描述(由申请人提供):认知能力下降是老年人最担心的衰老后果之一,即使是认知功能的微小变化也会严重影响功能、独立生活能力和生活质量。正常衰老的认知变化轨迹受遗传、认知储备、生活方式、虚弱和合并症等因素的影响。尽管有令人信服的数据表明癌症、癌症治疗和认知障碍之间存在关系,但绝大多数研究都集中在年轻患者(<65岁)身上,很少有研究集中在5年以上的幸存者身上。然而,大多数癌症幸存者是老年人。此外,那些在老年接受治疗的人可能更容易出现认知能力下降,因为影响正常认知能力老化的因素可能与癌症治疗相互作用,增加脆弱性。 本申请的目的是将老年医学、神经心理学、肿瘤学和遗传学领域结合起来,研究一组老年、长期(5-15岁)乳腺癌幸存者和匹配的健康对照人群中认知障碍的患病率和轨迹。采用前瞻性、纵向研究设计,我们将在控制合并症和虚弱的同时追求以下特定目标:目标1:检查APOE状态、吸烟史和治疗暴露对老年乳腺癌幸存者认知表现的相关性,与对照组相比目标2:利用生长混合模型技术确定老年乳腺癌幸存者和对照者认知功能纵向变化的轨迹(年龄、种族和教育匹配):目的3:探索认知储备、APOE、吸烟史和治疗暴露对研究入组时认知功能的影响以及纵向变化模式之间的关联。 这项研究意义重大,因为它将填补有关增加老年乳腺癌幸存者认知能力下降风险的因素的知识空白。这些数据对于权衡癌症治疗在日益老龄化的人口中的风险和益处至关重要。这项研究是创新的,因为它将检查治疗暴露,遗传多态性和吸烟史的相互作用,在预测乳腺癌幸存者和控制合并症和虚弱的负担之间的认知表现的差异。此外,纵向设计将告知轨迹是否
癌症幸存者的认知变化与健康对照相似(相移假说)或显示出更陡的斜率(加速老化假说)。这些数据将作为基础,以确定老年乳腺癌幸存者的认知障碍的风险,并指导
制定合理的干预措施来降低这种风险,最终目标是保护老年癌症幸存者的认知功能和福祉。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tim Alan Ahles其他文献
Tim Alan Ahles的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tim Alan Ahles', 18)}}的其他基金
Assessment of sensory gating, attention, and executive control in breast cancer
乳腺癌感觉门控、注意力和执行控制的评估
- 批准号:
10312035 - 财政年份:2018
- 资助金额:
$ 69.27万 - 项目类别:
Cognition In Older Breast Cancer Survivors: Treatment Exposure, APOE, & Smoking
老年乳腺癌幸存者的认知:治疗暴露、APOE、
- 批准号:
9120810 - 财政年份:2013
- 资助金额:
$ 69.27万 - 项目类别:
Cognition In Older Breast Cancer Survivors: Treatment Exposure, APOE, & Smoking
老年乳腺癌幸存者的认知:治疗暴露、APOE、
- 批准号:
8577351 - 财政年份:2013
- 资助金额:
$ 69.27万 - 项目类别:
Cognition In Older Breast Cancer Survivors: Treatment Exposure, APOE, & Smoking
老年乳腺癌幸存者的认知:治疗暴露、APOE、
- 批准号:
8741951 - 财政年份:2013
- 资助金额:
$ 69.27万 - 项目类别:
OLDER BREAST CANCER PATIENTS: RISK FOR COGNITIVE DECLINE
老年乳腺癌患者:认知能力下降的风险
- 批准号:
8067884 - 财政年份:2009
- 资助金额:
$ 69.27万 - 项目类别:
OLDER BREAST CANCER PATIENTS: RISK FOR COGNITIVE DECLINE
老年乳腺癌患者:认知能力下降的风险
- 批准号:
8465744 - 财政年份:2009
- 资助金额:
$ 69.27万 - 项目类别:
OLDER BREAST CANCER PATIENTS: RISK FOR COGNITIVE DECLINE
老年乳腺癌患者:认知能力下降的风险
- 批准号:
7589227 - 财政年份:2009
- 资助金额:
$ 69.27万 - 项目类别:
Older Breast Cancer Patients: Risk For Cognitive Decline
老年乳腺癌患者:认知能力下降的风险
- 批准号:
9238667 - 财政年份:2009
- 资助金额:
$ 69.27万 - 项目类别:
OLDER BREAST CANCER PATIENTS: RISK FOR COGNITIVE DECLINE
老年乳腺癌患者:认知能力下降的风险
- 批准号:
7849788 - 财政年份:2009
- 资助金额:
$ 69.27万 - 项目类别:
OLDER BREAST CANCER PATIENTS: RISK FOR COGNITIVE DECLINE
老年乳腺癌患者:认知能力下降的风险
- 批准号:
8254316 - 财政年份:2009
- 资助金额:
$ 69.27万 - 项目类别:
相似海外基金
3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
- 批准号:
10556192 - 财政年份:2023
- 资助金额:
$ 69.27万 - 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
- 批准号:
10315227 - 财政年份:2021
- 资助金额:
$ 69.27万 - 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
- 批准号:
443988 - 财政年份:2021
- 资助金额:
$ 69.27万 - 项目类别:
Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
- 批准号:
20K09011 - 财政年份:2020
- 资助金额:
$ 69.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
- 批准号:
19K09130 - 财政年份:2019
- 资助金额:
$ 69.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
- 批准号:
19K18225 - 财政年份:2019
- 资助金额:
$ 69.27万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
- 批准号:
18K16337 - 财政年份:2018
- 资助金额:
$ 69.27万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
- 批准号:
10005254 - 财政年份:2018
- 资助金额:
$ 69.27万 - 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
- 批准号:
9763320 - 财政年份:2018
- 资助金额:
$ 69.27万 - 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
- 批准号:
18K07341 - 财政年份:2018
- 资助金额:
$ 69.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




